Marius Hoeper, MD

Panelists discuss how pulmonary arterial hypertension diagnosis requires comprehensive evaluation including right heart catheterization to confirm hemodynamic criteria, with normal mean PA pressure being ≤20 mmHg and the need to rule out other causes of pulmonary hypertension.

Panelists discuss how the pathophysiology of pulmonary arterial hypertension involves complex mechanisms across multiple genetic and treatment pathways, with over 20 identified genes and four major therapeutic targets including nitric oxide, endothelin, prostacyclin, and activin signaling inhibition.

Marius Hoeper, MD, describes the role clinicians can play in advocating for health care system reforms that could address the economic implications of PAH and discusses the key unmet needs in the PAH treatment landscape.

Following a review of strategies and care delivery models that could help optimize the management of PAH, Marius Hoeper, MD, discusses his recent publication on the long-term impact of sotatercept on morbidity and mortality.

Marius Hoeper, MD, offers expert perspectives on the recently FDA-approved sotatercept, focusing on its mechanism of action, potential cost implications, and potential advantages and disadvantages it could offer compared with existing foundational therapies.

An expert on pulmonary arterial hypertension discusses the potential impact of emerging therapies, including sotatercept, ralinepag, and inhaled imatinib.

Marius Hoeper, MD, discusses the direct medical costs and indirect socioeconomic costs associated with the treatment of pulmonary arterial hypertension (PAH), including hospitalizations, outpatient care, and patient productivity and quality of life.